EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults

Lisa A Prosser, Megan Wallace, Angela M Rose, Kerra Mercon, Cara B Janusz, Acham Gebremariam, David W Hutton, Andrew J Leidner, Fangjun Zhou, Ismael R Ortega-Sanchez, Danielle Moulia, Ruth Link-Gelles und 3 weitere

JAMA Network Open · 07.08.2025 · 8 (8) · e2523688

DOI: 10.1001/jamanetworkopen.2025.23688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 07.08.2025. Verfasst von Lisa A Prosser und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, COVID-19, COVID-19 Vaccines, Vaccination. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Evidence is needed on the economic favorability of a 2023-2024 COVID-19 vaccination program to support policy decisions on recommendations for COVID-19 vaccination.

Objective

To measure the cost-effectiveness of vaccination with a 2023-2024 COVID-19 mRNA vaccine in adults aged 18 years or older compared with no updated vaccination (with a 2023-2024 vaccine). Design, Setting, and Participants This decision analytic modeling study used a simulation model to compare outcomes for hypothetical cohorts of vaccinated and unvaccinated, immunocompetent adults stratified by age (18-49 years, 50-64 years, and ≥65 years). Parameters were drawn from primary and published data to represent characteristics of the US adult population. The interventions included vaccination with a 2023-2024 mRNA vaccine against COVID-19–associated illness compared with no updated vaccination (with a 2023-2024 vaccine) using a 1-year analytic time frame. A phase 2 analysis also considered an intervention strategy of vaccination with an additional dose of 2023-2024 COVID-19 mRNA vaccine. Main Outcome and Measure The incremental cost-effectiveness ratio as reported in 2023 US dollars per quality-adjusted life-year.

Results

Vaccination averted substantial numbers of cases, hospitalizations, intensive care unit stays, and deaths across age groups. For adults aged 18 to 49 years and 50 to 64 years, vaccination yielded incremental cost-effectiveness ratios of $115 588 and $25 787 per quality-adjusted life-year gained, respectively. For individuals aged 65 years or older, vaccination was cost saving. Sensitivity analyses indicated that the results were most sensitive to the cost per vaccine dose, vaccine effectiveness, and probability of hospitalization. In phase 2 analyses, an additional dose strategy was only economically favorable in higher-risk scenarios for individuals aged 65 years or older. Conclusions and Relevance In this modeling study, economic favorability of COVID-19 vaccination varied by age. Cost-effectiveness results for individuals in the 2 older age groups were favorable and generally robust to changes in parameter inputs, while results for the younger age group were sensitive to parameter input changes. As the evidence base for COVID-19 vaccination and burden of illness evolves, it may be important to continue to update and revise the economic evaluation of vaccination. The Advisory Committee on Immunization Practices considered these results in its decision to recommend vaccination with the 2023 to 2024 COVID-19 mRNA vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisCOVID-19COVID-19 VaccinesVaccinationHumansAdultMiddle AgedUnited StatesAgedAdolescentSARS-CoV-2Young AdultMaleFemaleQuality-Adjusted Life Years

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor.
  • Susan B. Meister Child Health Evaluation and Research Center, University of Michigan Medical School, Ann Arbor.
  • Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
  • Public Health Service, Commissioned Corps, Rockville, Maryland.

Zitieren

APA

Prosser, L. A., Wallace, M., Rose, A. M., Mercon, K., Janusz, C. B., Gebremariam, A., Hutton, D. W., Leidner, A. J., Zhou, F., Ortega-Sanchez, I. R., Moulia, D., Link-Gelles, R., Saydah, S., Shah, M., & Pike, J. (2025). Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults. JAMA Network Open, 8(8), e2523688. https://doi.org/10.1001/jamanetworkopen.2025.23688

Vancouver

Prosser LA, Wallace M, Rose AM, Mercon K, Janusz CB, Gebremariam A, et al. Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults. JAMA Network Open. 2025;8(8):e2523688. doi:10.1001/jamanetworkopen.2025.23688

BibTeX
@article{Prosser2025,
  author = {Prosser, Lisa A and Wallace, Megan and Rose, Angela M and Mercon, Kerra and Janusz, Cara B and Gebremariam, Acham and Hutton, David W and Leidner, Andrew J and Zhou, Fangjun and Ortega-Sanchez, Ismael R and Moulia, Danielle and Link-Gelles, Ruth and Saydah, Sharon and Shah, Melisa and Pike, Jamison},
  title = {Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {8},
  pages = {e2523688},
  doi = {10.1001/jamanetworkopen.2025.23688}
}
Kostenlos starten →